Brickwork

BrickBio is a preclinical-stage biotechnology company specializing in the development of precision biologics through a proprietary protein engineering platform. The company's core technology utilizes an expanded genetic code to incorporate synthetic amino acids into proteins within living cells, enabling site-specific and site-selective bioconjugation. This approach allows for the creation of next-generation antibody-drug conjugates (ADCs), AAV gene therapies, and other complex biologics with improved therapeutic windows, half-life, and efficacy. BrickBio actively builds an internal pipeline focused on oncology and immunology while maintaining multiple high-profile partnerships with pharmaceutical companies to co-develop novel therapeutic candidates.